Linkedin-in

Investor Relations

Lipocine is a biopharmaceutical company leveraging its proprietary technology platform to develop innovative products with effective oral delivery. 

Company Profile

ABOUT LIPOCINE INC.

Lipocine is a biopharmaceutical company leveraging its proprietary technology platform to develop innovative products with effective oral delivery.

Our drug candidates represent enablement of differentiated, patient friendly oral options with favorable benefit to risk profiles which target large addressable markets with significant unmet medical needs.

 

Management Directors

Press Releases
Jun 4, 2026
Lipocine Inc. to Host Virtual KOL Event Highlighting Unmet Needs in Postpartum Depression and the Clinical Profile of LPCN 1154

Live webinar to take place on Friday, June 12, 2026 at 11:00 AM Eastern Time SALT LAKE CITY, June 4, 2026 /PRNewswire/ -- Lipocine Inc. (Nasdaq: LPCN), a specialty pharmaceutical company focused...

May 19, 2026
Lipocine Announces LPCN 1154 Phase 3 Data Accepted for Oral Presentation at 2026 ASCP Annual Meeting

Lipocine Inc. (NASDAQ: LPCN), a biopharmaceutical company leveraging its proprietary technology platform to augment therapeutics through effective oral delivery, today announced that its Phase 3...

May 18, 2026
Lipocine to Present at A.G.P.'s Annual Virtual Healthcare Company Showcase

Lipocine Inc. (NASDAQ: LPCN), a biopharmaceutical company leveraging its proprietary technology platform to augment therapeutics through effective oral delivery, today announced that management...

May 7, 2026
Lipocine Announces Financial Results for the First Quarter Ended March 31, 2026

Lipocine Inc. (NASDAQ: LPCN), a biopharmaceutical company leveraging its proprietary technology platform to augment therapeutics through effective oral delivery, today announced financial results...

STOCK INFO
NASDAQLPCN
SEC FILINGS
NASDAQLPCN

Innovating beyond boundaries for patients

Krista Fogarty phone: (801) 994-7383 email: kf@lipocine.com